Jasper Therapeutics (NASDAQ:JSPR) Price Target Lowered to $6.00 at JMP Securities

Jasper Therapeutics (NASDAQ:JSPR) had its price objective trimmed by JMP Securities from $12.00 to $6.00 in a research note published on Monday,Benzinga reports. The firm currently has a market outperform rating on the stock.

Several other research firms also recently issued reports on JSPR. Royal Bank Of Canada downgraded Jasper Therapeutics from an “outperform” rating to a “sector perform” rating and set a $5.00 price objective for the company. in a research note on Tuesday, July 8th. William Blair reaffirmed a “market perform” rating on shares of Jasper Therapeutics in a research note on Monday, July 7th. Cantor Fitzgerald downgraded Jasper Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, July 7th. HC Wainwright lowered their price objective on Jasper Therapeutics from $40.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, July 7th. Finally, BTIG Research decreased their target price on shares of Jasper Therapeutics from $20.00 to $7.00 and set a “buy” rating for the company in a research report on Monday. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $25.63.

Jasper Therapeutics Price Performance

JSPR stock opened at $2.54 on Monday. The company has a 50 day simple moving average of $2.86 and a 200 day simple moving average of $4.18. The stock has a market cap of $41.19 million, a price-to-earnings ratio of -0.42 and a beta of 2.77. Jasper Therapeutics has a 1 year low of $2.27 and a 1 year high of $26.05.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.54). On average, equities research analysts anticipate that Jasper Therapeutics will post -4.47 EPS for the current fiscal year.

Hedge Funds Weigh In On Jasper Therapeutics

A number of institutional investors have recently modified their holdings of JSPR. Acadian Asset Management LLC acquired a new position in shares of Jasper Therapeutics during the first quarter worth approximately $46,000. Marex Group plc acquired a new position in shares of Jasper Therapeutics during the second quarter worth approximately $74,000. Engineers Gate Manager LP acquired a new position in shares of Jasper Therapeutics during the second quarter worth approximately $78,000. Corton Capital Inc. acquired a new position in shares of Jasper Therapeutics during the first quarter worth approximately $113,000. Finally, XTX Topco Ltd acquired a new position in shares of Jasper Therapeutics during the second quarter worth approximately $152,000. 79.85% of the stock is owned by institutional investors and hedge funds.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.